Close Menu
News JournosNews Journos
  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Turkey Reports
  • Money Watch
  • Health
Editors Picks

Record Levels of Tesla Owners Trading in EVs

March 20, 2025

Trump Deploys Additional 2,000 National Guard Troops to Los Angeles

June 19, 2025

Trump Issues Pardons Amidst Political Landscape Changes

March 25, 2025

Illegal Immigrants Charged with Smuggling Asylum Seekers from Canada to U.S.

May 3, 2025

Trump to Unveil New Tariffs on “Liberation Day” as Price Concerns Rise

April 2, 2025
Facebook X (Twitter) Instagram
Latest Headlines:
  • Trump’s 50% Copper Tariff May Increase Prices for Appliances, EVs, and More, Experts Say
  • Three Canadians, Including Two Military Members, Charged in Anti-Government Militia Plot
  • Trump and Netanyahu Announce Imminent Hamas Ceasefire Deal
  • ErdoÄŸan’s Criminal Record Allegations Linked to Shoe Boxes
  • Trump Administration Files Lawsuit Against California Over Transgender Athlete Policies
  • Oak View Group CEO Faces Bid Rigging Charges in Utah Arena Deal
  • Fed Officials Expect Rate Cuts, but Divergence in Predictions Noted in Minutes
  • First Step Toward Honorable Peace Launched
  • Residents Protest Gentrification in Mexico City Amid Overtourism Concerns
  • Red State Collaborates with PragerU on Teacher Licensure Assessment
  • Google Secures 200 MW Fusion Energy Deal for AI Projects
  • Report Links 13 Suicides to U.K. Post Office Wrongful Convictions Scandal
  • Five Strategies to Lower Your Student Loan Payments Now
  • Nvidia Hits Milestone as First Company to Reach $4 Trillion Valuation
  • Eli Manning Declines Ownership Bid Opportunity
  • New Aid Distribution Model for Gaza Seeks to Bypass Hamas Interference
  • Can You Prevent Mark Zuckerberg from Using Your Art on Facebook?
  • McDonald’s Revamps Menu with New Snack Wraps and Spicy McMuffins to Attract Customers
  • Art Detective Reclaims Stolen Centuries-Old Documents
  • Trump Issues New Letters Imposing Higher Tariff Rates Globally
Facebook X (Twitter) Instagram
News JournosNews Journos
Subscribe
Wednesday, July 9
  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Turkey Reports
  • Money Watch
  • Health
News JournosNews Journos
You are here: News Journos » Business » Generic Semaglutide Available from Hims & Hers as Novo Nordisk Patent Expires
Generic Semaglutide Available from Hims & Hers as Novo Nordisk Patent Expires

Generic Semaglutide Available from Hims & Hers as Novo Nordisk Patent Expires

News EditorBy News EditorJuly 9, 2025 Business 5 Mins Read

Hims & Hers Health has announced its plan to introduce generic semaglutide in Canada, a development made possible due to the impending expiration of Novo Nordisk’s patent on its brand-name drugs, Ozempic and Wegovy. This move marks Hims & Hers’ first venture into the Canadian market, where the potential for this generic drug is significant. The company aims to provide affordable weight-loss care, emphasizing personalized health services in conjunction with the new offerings.

Article Subheadings
1) Overview of Hims & Hers Announcement
2) The Role of Generic Medications
3) Financial Impacts on the Canadian Market
4) Novo Nordisk’s Patent Situation
5) Future Steps for Hims & Hers in Canada

Overview of Hims & Hers Announcement

On Wednesday, a press release from Hims & Hers Health revealed plans to offer a generic version of semaglutide in Canada. This drug is commonly associated with the branded treatments Ozempic and Wegovy that are produced by Novo Nordisk. The timing of this announcement aligns with the impending expiration of Novo Nordisk’s patent in January. Andrew Dudum, CEO of Hims & Hers, articulated the company’s vision, stating, “Canada is a major opportunity to show what affordable, high-quality weight loss care can look like.” He emphasized the importance of combining affordability with personalized care to make the treatment accessible to a larger population.

The Role of Generic Medications

Generic medications, such as the planned semaglutide offering from Hims & Hers, are copies of brand-name drugs that are required to meet the same safety and efficacy standards once a patent has expired. These generics are produced without the extensive costs associated with developing new drugs. Unlike compounded versions, generics are available in standard dosages and formulations. This makes them a viable and affordable option for patients seeking treatment for conditions such as obesity. The introduction of generics often prompts increased competition in the market, potentially leading to lower prices and wider availability for consumers.

Financial Impacts on the Canadian Market

The Canadian semaglutide market has shown considerable growth, with revenues reaching approximately $1.18 billion in 2024. Projections indicate that this market is poised to expand substantially, potentially rising to $4.03 billion by 2035, according to reports by Grand View Research. This remarkable growth presents a significant opportunity for Hims & Hers as they venture into this domain. Currently, no generic version of semaglutide has been approved by Canadian health authorities, although the approval processes have commenced for various competitors in the field. This regulatory landscape is crucial for companies seeking to enter the market, as it dictates the timeline and process through which they can offer their products.

Novo Nordisk’s Patent Situation

Novo Nordisk has faced challenges regarding the maintenance of its semaglutide patent in Canada. Official documents reveal that the company failed to pay the necessary maintenance fees for its patent, which lapsed in 2020. This lapse occurred despite a one-year grace period, during which they could have rectified the situation. Correspondence from Canadian authorities indicates that once a patent has lapsed, it cannot be revived. This situation has opened the door for Hims & Hers to introduce its generic offerings, highlighting the importance of vigilant patent management in the pharmaceutical industry.

Future Steps for Hims & Hers in Canada

Following the announcement of their plans to sell generic semaglutide, Hims & Hers may also consider various regulatory aspects to ensure compliance in the Canadian market. While they have not confirmed any specific steps toward applying for approval, the company has indicated they are collaborating with an approved partner to adhere to local laws. Furthermore, this move follows the recent acquisition of European telehealth platform Zava, which enhances their capabilities and reach in Europe. This comprehensive strategy could position Hims & Hers as a key player in the health-tech landscape in both Canada and Europe, providing innovative solutions to healthcare challenges.

No. Key Points
1 Hims & Hers will introduce generic semaglutide in Canada as Novo Nordisk’s patent edges toward expiration.
2 Generic medications are key for competitive market pricing and accessibility for patients.
3 The Canadian semaglutide market is projected to grow significantly, providing a substantial opportunity for Hims & Hers.
4 Novo Nordisk’s failure to maintain its patent opens avenues for other companies to enter the market.
5 Collaborative efforts and strategic acquisitions will enhance Hims & Hers’ position in both Canadian and European health markets.

Summary

The announcement by Hims & Hers Health to introduce generic semaglutide in Canada signifies a notable turn in the pharmaceutical landscape, particularly in the weight-loss drug market. As the patent for Novo Nordisk approaches expiration, the entry of generics holds promise for increased accessibility and affordability of vital treatments. The financial growth projections for the Canadian market further emphasize the potential impact of this move on both consumers and the healthcare system at large.

Frequently Asked Questions

Question: What is semaglutide used for?

Semaglutide is primarily used for the treatment of obesity and related metabolic conditions. It helps in weight loss by regulating appetite and may also be prescribed for managing type 2 diabetes.

Question: How does the approval process for generic medications work in Canada?

In Canada, generic medications must undergo a regulatory review by Health Canada to ensure they meet safety and efficacy standards before they can be marketed and sold.

Question: What implications does a patent expiration have for pharmaceutical companies?

When a patent expires, other companies can produce and sell generic versions of the drug, which often leads to increased competition, lower prices, and broader access to treatments for patients.

Business Ethics Business Growth Business News Business Technology Consumer Trends Corporate Finance Corporate Strategy Economic Outlook Entrepreneurship Expires Generic Global Business Hims Innovation Investment Opportunities Leadership Management Market Trends Mergers & Acquisitions Nordisk Novo Patent Retail Business Semaglutide Small Business Startups Supply Chain
Share. Facebook Twitter Pinterest LinkedIn Email Reddit WhatsApp Copy Link Bluesky
News Editor
  • Website

As the News Editor at News Journos, I am dedicated to curating and delivering the latest and most impactful stories across business, finance, politics, technology, and global affairs. With a commitment to journalistic integrity, we provide breaking news, in-depth analysis, and expert insights to keep our readers informed in an ever-changing world. News Journos is your go-to independent news source, ensuring fast, accurate, and reliable reporting on the topics that matter most.

Keep Reading

Business

Eli Manning Declines Ownership Bid Opportunity

5 Mins Read
Business

Trump Proposes 200% Tariffs on Pharmaceuticals

5 Mins Read
Business

Boeing Achieves Highest Airplane Deliveries Since Late 2023 with Increased 737 Max Production

4 Mins Read
Business

Netflix’s Strategy to Attract Top Directors from Traditional Film Industry

6 Mins Read
Business

Apple’s F1 Becomes Its Highest-Grossing Theatrical Release

6 Mins Read
Business

Family Offices Intensify Investments in Biotech and Pharma in June

5 Mins Read
Mr Serdar Avatar

Serdar Imren

News Director

Facebook Twitter Instagram
Journalism Under Siege
Editors Picks

Study Reveals Strong U.S. Support for Climate Policies Despite EPA Rollbacks

March 14, 2025

Bipartisan Senate Vote Opposes Trump Tariffs on Canada

April 2, 2025

California Sues Trump to Halt Tariffs

April 16, 2025

Trump Signal Chat Leak Poses Ongoing Security Risk, Warns Former Intelligence Official

March 30, 2025

Elon Musk Embraces ‘Dark MAGA’ Image at CPAC with Chainsaw Prop

February 20, 2025

Subscribe to News

Get the latest sports news from NewsSite about world, sports and politics.

Facebook X (Twitter) Pinterest Vimeo WhatsApp TikTok Instagram

News

  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Money Watch

Journos

  • Top Stories
  • Turkey Reports
  • Health
  • Tech
  • Sports
  • Entertainment

COMPANY

  • About Us
  • Get In Touch
  • Our Authors
  • Privacy Policy
  • Terms and Conditions
  • Accessibility

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

© 2025 The News Journos. Designed by The News Journos.

Type above and press Enter to search. Press Esc to cancel.

Ad Blocker Enabled!
Ad Blocker Enabled!
Our website is made possible by displaying online advertisements to our visitors. Please support us by disabling your Ad Blocker.